Lyell Immunopharma, Inc.
Clinical trials sponsored by Lyell Immunopharma, Inc., explained in plain language.
-
Double-Pronged attack: new cell therapy targets tough lymphoma
Disease control Recruiting nowThis study tests a new treatment called ronde-cel for people with aggressive B-cell lymphoma that has come back or not responded to at least two prior therapies. The therapy uses a patient's own immune cells, which are modified to recognize and attack two markers on cancer cells …
Phase: PHASE1, PHASE2 • Sponsor: Lyell Immunopharma, Inc. • Aim: Disease control
Last updated May 17, 2026 04:34 UTC
-
Double-Targeting CAR t therapy aims to outperform standard treatment in lymphoma
Disease control Recruiting nowThis study tests a new cell therapy called ronde-cel that targets two proteins (CD19 and CD20) on lymphoma cells, compared to standard CAR T-cell therapy that targets only one. About 400 adults with large B-cell lymphoma that came back or didn't respond to first treatment will ta…
Phase: PHASE3 • Sponsor: Lyell Immunopharma, Inc. • Aim: Disease control
Last updated May 17, 2026 04:30 UTC
-
Engineered immune cells take on Hard-to-Treat colon cancer
Disease control Recruiting nowThis early-stage study tests a new treatment called GCC19CART for people with metastatic colorectal cancer that has come back or not responded to standard therapies. The treatment uses a patient's own immune cells, modified to target cancer cells. The main goals are to check safe…
Phase: PHASE1 • Sponsor: Lyell Immunopharma, Inc. • Aim: Disease control
Last updated May 15, 2026 11:56 UTC